Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
Denodo, a leader in data management, announced that it has integrated NVIDIA NIM inference microservices into the Denodo Platform, as part of its focus on bolstering its rapidly expanding artificial intelligence (AI) capabilities.
The Denodo Platform's logical data management capabilities, combined with NVIDIA NIM, enable enterprise customers to:
- Rapidly curate and transform data into AI-ready pipelines to feed large language models (LLMs)
- Improve model accuracy and combat hallucinations by accessing trusted enterprise data through retrieval augmented generation (RAG) pipelines.
- Simplify secure, real-time access to distributed enterprise knowledge for generative AI applications
- Maintain data privacy/security and enforce granular access controls for AI models that access organizational data
- Fast-track AI/ML deployments from data prep to model scoring with NVIDIA NeMo, leveraging an integrated data fabric for enterprise data input into this process
NVIDIA NIM is a collection of cloud-native microservices that simplify and accelerate the deployment of generative AI models across a variety of environments, including the cloud, on-premises data centers, and workstations. It connects the power of the latest foundational AI models, securely deployed on NVIDIA’s accelerated infrastructure, with enterprise customers everywhere.
The Denodo Platform’s integration of NVIDIA NIM helps customers seamlessly leverage advanced AI capabilities within their data management workflows. It also helps enable enterprises to deploy and scale generative AI applications with unprecedented speed and efficiency. Key use cases include improved analytics and robust AI-driven insights across such verticals as financial services, healthcare, retail, and manufacturing, accelerating time to insight from diverse data sources. As an NVIDIA Metropolis partner, Denodo is working to deploy vision AI and vision language model (VLM) NIM microservices to streamline industrial processes and increase worker safety.
Using the Denodo Platform with NVIDIA NeMo can significantly boost SQL query generation accuracy for LLMs. RAG capabilities enable more trustworthy responses by enabling models to retrieve relevant knowledge from the data fabric before generating output, and the Denodo Platform helps to simplify and accelerate data access, while reducing errors, when models query the platform.
By integrating NVIDIA NIM, Denodo helps ensure that customers will be able to maintain full control over their AI deployments, whether on premises or in the cloud. The integration is set to deliver significant business benefits, including accelerated time to value and enhanced security for AI applications.
“I am thrilled by this integration, and I think it's a sign of the direction in which Denodo's logical data management capabilities can take us,” said Narayan Sundar, Senior Director-Strategic Alliances at Denodo. “Denodo is at the forefront of supporting RAG-enabled GenAI applications with real-time, governed, trusted data from an organization’s vast data estates, and I look forward to seeing the innovations, as they start to emerge, from enterprise customers that leverage the Denodo Platform with NVIDIA NIM integration.”
Learn more about the Denodo Platform with NVIDIA NIM integration.
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602559183/en/
Contact information
Media
pr@denodo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas12.1.2026 14:30:00 EET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol for botensilimab (BOT) plus balstilimab (BAL) under France’s Autorisation d’Accès Compassionnel (AAC) framework. The updated protocol expands France’s previously granted AAC authorization for BOT+BAL in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases to eligible patients with certain ovarian cancers and soft-tissue sarcomas—diseases with substantial unmet medical need after standard options have been exhausted. The revised protocol is designed to broaden the eligibility criteria, allowing more patients with advanced solid tumors to have early access to BOT+BAL under reimbursed compassionate use, and to enhance monitoring and treatment procedures in participating hospitals. BOT+BAL is a chemotherapy- and radiation-f
Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands12.1.2026 14:30:00 EET | Press release
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity. Cell therapy manufacturing is patient-specific and time-sensitive, making regional production capacity increasingly important as programs advance from clinical development toward commercial supply. The new Netherlands hub is designed to provide European drug developers with access to automated manufacturing infrastructure, while maintaining alignment to a common production standard across Cellares’ global facilities. The leased premises comprise approximately 9,741 square meters (about 105,000 square feet LFA) of laboratory and office space within the Nexus building in Leiden, a newly construct
Lilac and Traxys Announce Binding 10-Year Offtake Agreement for Great Salt Lake Lithium Production12.1.2026 14:00:00 EET | Press release
Lilac Solutions, a leading provider of direct lithium extraction technology, and Traxys North America, a leading global physical trader and merchant in metals and natural resources, today announced a binding 10-year offtake agreement for lithium carbonate produced at Lilac's Great Salt Lake facility in Utah. The agreement represents a major milestone in advancing the project toward construction and establishes a clear commercial pathway for one of the nearest-term domestic lithium projects in the United States. Under the terms of the definitive agreement, Traxys will purchase 50,000 tonnes of lithium carbonate over a 10-year period, representing 100% of the planned Phase 1 production capacity. The agreement is take-or-pay, with agreed pricing mechanisms linked to market indices. The Great Salt Lake Phase 1 facility is designed to produce 5,000 tonnes per annum of battery-grade lithium carbonate, which would nearly double current U.S. lithium carbonate production. The project leverages
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 07:00:00 EET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 03:15:00 EET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom